NCDL

Nuveen Churchill Direct Lending Corp. (NCDL) Q1 2025 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2025. Nuveen Churchill Direct Lending Corp. is a closed-end, externally managed business development company (BDC) and regulated investment company (RIC). The Company invests primarily in senior secured loans to private equity-owned U.S. middle market companies. As of May 6, 2025, there were 50,281,364 shares of common stock outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• Operating Performance: Net investment income decreased by approximately 7.7% compared to Q1 2024, primarily due to a decline in the weighted average yield of the portfolio (10.10% vs. 11.55% in Q1 2024) driven by lower base interest rates, partially offset by increased investment activity.
• Unrealized Losses: The Company recorded a net unrealized loss of $13.5 million in Q1 2025, a significant reversal from the $4.1 million unrealized gain in Q1 2024. This was attributed to the underperformance of certain portfolio companies despite stable market spreads.
• Debt Structure: Total debt increased by approximately $87 million. Notable changes include the issuance of $300 million in 6.650% Notes due 2030 in January 2025 and the refinancing of the CLO-I facility (2022 Debt Securitization) with a new $458 million facility (CLO-I Refinancing) in March 2025. The Wells Fargo Financing Facility was terminated in January 2025.
• Share Repurchases: The Company repurchased approximately 706,657 shares in March 2025 alone under its 10b5-1 plan. Cumulative repurchases since inception total over 4.1 million shares.

Guidance, Outlook, and Risks

• Market Outlook: Management notes that private equity M&A activity slowed in Q1 2025 as investors assessed the impact of tariffs. Prepayment activity returned to normalized levels due to refinancing. The Company is monitoring the impact of trade policies and tariffs on portfolio companies, focusing on defensive businesses with strong free cash flow.
• Asset Quality: As of March 31, 2025, two portfolio companies were on non-accrual status with an aggregate fair value of $7.3 million (0.35% of total investments). The weighted average internal risk rating of the portfolio was 4.14.
• Liquidity: The Company maintains adequate liquidity with $49.2 million in cash and $172.8 million available under its Revolving Credit Facility. An At-The-Market (ATM) equity offering program with up to $200 million capacity was established in March 2025, though no shares have been issued yet.
• Risks: Key risks include interest rate volatility, the impact of U.S. tariff and trade policies on portfolio companies, and the potential for credit deterioration in the middle market. The Company utilizes interest rate swaps to hedge fixed-rate liabilities.

Key Facts for Investor Verification

• Fee Waivers: The Adviser waived income-based incentive fees of $2.3 million for Q1 2025, consistent with the waiver period through the first five quarters post-IPO.
• Dividend Policy: A regular dividend of $0.45 per share was declared on April 30, 2025, payable in July 2025. A special dividend of $0.10 per share was also paid in Q1 2025.
• Portfolio Composition: The portfolio is heavily weighted toward Healthcare & Pharmaceuticals (16.5%) and Services: Business (16.3%). Approximately 94.6% of debt investments bear floating interest rates.
• Debt Maturities: Significant debt maturities are concentrated beyond 5 years due to the CLO structures, with the 2030 Notes maturing in March 2030.